Phase II trial of ethinylestradiol for aromatase inhibitor-resistant postmenopausal advanced/recurrent breast cancer patients
Not Applicable
- Conditions
- aromatase inhibitor-resistant advanced/recurrent breast cancer
- Registration Number
- JPRN-UMIN000015698
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Inflammatory breast cancer 2. Any malignant neoplasms 3. Severe cardiac disease(e.g. myocardial infarction, valvular disease, heart failure) 4. Liver cirrhosis 5. Thrombosis 6. Judged inappropriate by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate; RR
- Secondary Outcome Measures
Name Time Method Clinical Benefit Rate; CBR Adverse Drug Reaction; ADR Progression-Free Survival; PFS